.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,153,616

« Back to Dashboard

Claims for Patent: 8,153,616

Title:Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.
Inventor(s): Zeun; Susan (Berlin, DE), Boudes; Pol (Hackettstown, NJ), Secci; Angelo (Parsipanny, NJ), Nedrikat; Jan (Chianti Kirkland, CA), Zimmermann; Holger (Falkensee, DE)
Assignee: Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/609,705
Patent Claims: 1. A method of treating dysfunctional uterine bleeding and of oral contraception, comprising orally administering to a woman in need of treatment for dysfunctional uterine bleeding and desiring oral contraception, over at least one treatment cycle of 28 days, one dosage unit comprising 3 mg of estradiol valerate daily for 2 days, then one dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5 days, then one dosage unit comprising 2 mg of estradiol valerate and 3 mg of dienogest daily for 17 days, then one dosage unit comprising 1 mg of estradiol valerate daily for 2 days, and then one dosage unit comprising a pharmaceutically acceptable placebo daily for 2 days.

2. The method of claim 1, comprising six of said treatment cycles of 28 days.

3. A method of treating dysfunctional uterine bleeding and of oral contraception, comprising orally administering to a woman in need of treatment for dysfunctional uterine bleeding and desiring oral contraception, over at least one treatment cycle of 28 days, a first phase of 2 daily oral dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily oral dosage units, a first group comprising 5 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily oral dosage units, each of which comprises 2, mg of estradiol valerate and valerate and 3 mg of dienogest; a third phase of 2 daily oral dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 daily oral dosage units, each comprising a pharmaceutically acceptable placebo.

4. The method of claim 3, comprising six of said treatment cycles of 28 days.

5. A method of treating dysfunctional uterine bleeding, comprising orally administering to a woman in need of treatment for dysfunctional uterine bleeding, over at least one treatment cycle of 28 days, a first phase of 2 daily oral dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily oral dosage units, a first group comprising 5 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily oral dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 daily oral dosage units, each comprising a pharmaceutically acceptable placebo.

6. The method of claim 5, comprising six of said treatment cycles of 28 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc